Literature DB >> 23358186

Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors.

Richard A Voit1, Moira A McMahon, Sara L Sawyer, Matthew H Porteus.   

Abstract

Restriction factors constitute a newly appreciated line of innate immune defense, blocking viral replication inside of infected cells. In contrast to these antiviral proteins, some cellular proteins, such as the CD4, CCR5, and CXCR4 cell surface receptors, facilitate HIV replication. We have used zinc finger nucleases (ZFNs) to insert a cocktail of anti-HIV restriction factors into the CCR5 locus in a T-cell reporter line, knocking out the CCR5 gene in the process. Mirroring the logic of highly active antiretroviral therapy, this strategy provides multiple parallel blocks to infection, dramatically limiting pathways for viral escape, without relying on random integration of transgenes into the genome. Because of the combination of blocks that this strategy creates, our modified T-cell lines are robustly resistant to both CCR5-tropic (R5-tropic) and CXCR4-tropic (X4-tropic) HIV-1. While zinc finger nuclease-mediated CCR5 disruption alone, which mimics the strategy being used in clinical trials, confers 16-fold protection against R5-tropic HIV, it has no effect against X4-tropic virus. Rhesus TRIM5α, chimeric human-rhesus TRIM5α, APOBEC3G D128K, or Rev M10 alone targeted to CCR5 confers significantly improved resistance to infection by both variants compared with CCR5 disruption alone. The combination of three factors targeted to CCR5 blocks infection at multiple stages, providing virtually complete protection against infection by R5-tropic and X4-tropic HIV.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358186      PMCID: PMC3616536          DOI: 10.1038/mt.2012.284

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain.

Authors:  Sara L Sawyer; Lily I Wu; Michael Emerman; Harmit S Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-02       Impact factor: 11.205

Review 2.  Intracellular restriction factors in mammalian cells--An ancient defense system finds a modern foe.

Authors:  Jörg G Baumann
Journal:  Curr HIV Res       Date:  2006-04       Impact factor: 1.581

3.  T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication.

Authors:  Christina Ochsenbauer-Jambor; Jennifer Jones; Marintha Heil; Kenneth P Zammit; Olaf Kutsch
Journal:  Biotechniques       Date:  2006-01       Impact factor: 1.993

4.  HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation.

Authors:  Mariana Santa-Marta; Frederico Aires da Silva; Ana Margarida Fonseca; Joao Goncalves
Journal:  J Biol Chem       Date:  2004-12-20       Impact factor: 5.157

5.  Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells.

Authors:  Greg M Podsakoff; Barbara C Engel; Denise A Carbonaro; Chris Choi; Elzbieta M Smogorzewska; Gerhard Bauer; David Selander; Susan Csik; Kathy Wilson; Michael R Betts; Richard A Koup; Gary J Nabel; Keith Bishop; Steven King; Manfred Schmidt; Christof von Kalle; Joseph A Church; Donald B Kohn
Journal:  Mol Ther       Date:  2005-07       Impact factor: 11.454

6.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

7.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

8.  Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals.

Authors:  U Ranga; C Woffendin; S Verma; L Xu; C H June; D K Bishop; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

9.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

Authors:  Marion G Ott; Manfred Schmidt; Kerstin Schwarzwaelder; Stefan Stein; Ulrich Siler; Ulrike Koehl; Hanno Glimm; Klaus Kühlcke; Andrea Schilz; Hana Kunkel; Sonja Naundorf; Andrea Brinkmann; Annette Deichmann; Marlene Fischer; Claudia Ball; Ingo Pilz; Cynthia Dunbar; Yang Du; Nancy A Jenkins; Neal G Copeland; Ursula Lüthi; Moustapha Hassan; Adrian J Thrasher; Dieter Hoelzer; Christof von Kalle; Reinhard Seger; Manuel Grez
Journal:  Nat Med       Date:  2006-04-02       Impact factor: 53.440

10.  Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay.

Authors:  Dalma Vödrös; Eva Maria Fenyö
Journal:  Methods Mol Biol       Date:  2005
View more
  32 in total

1.  Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing.

Authors:  Ayal Hendel; Eric J Kildebeck; Eli J Fine; Joseph Clark; Niraj Punjya; Vittorio Sebastiano; Gang Bao; Matthew H Porteus
Journal:  Cell Rep       Date:  2014-03-27       Impact factor: 9.423

2.  Hematopoietic cell transplantation and HIV cure: where we are and what next?

Authors:  Shimian Zou; Simone Glynn; Daniel Kuritzkes; Monica Shah; Nakela Cook; Nancy Berliner
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

Review 3.  Recent developments and clinical studies utilizing engineered zinc finger nuclease technology.

Authors:  Young-Il Jo; Hyongbum Kim; Suresh Ramakrishna
Journal:  Cell Mol Life Sci       Date:  2015-06-19       Impact factor: 9.261

4.  Cellular HIV-1 inhibition by truncated old world primate APOBEC3A proteins lacking a complete deaminase domain.

Authors:  Miki Katuwal; Yaqiong Wang; Kimberly Schmitt; Kejun Guo; Kalani Halemano; Mario L Santiago; Edward B Stephens
Journal:  Virology       Date:  2014-09-28       Impact factor: 3.616

Review 5.  The clinical applications of genome editing in HIV.

Authors:  Cathy X Wang; Paula M Cannon
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

Review 6.  Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.

Authors:  Nicole J Piscopo; Katherine P Mueller; Amritava Das; Peiman Hematti; William L Murphy; Sean P Palecek; Christian M Capitini; Krishanu Saha
Journal:  Biotechnol J       Date:  2017-09-18       Impact factor: 4.677

7.  Clinical Applications of Genome Editing to HIV Cure.

Authors:  Cathy X Wang; Paula M Cannon
Journal:  AIDS Patient Care STDS       Date:  2016-11-17       Impact factor: 5.078

Review 8.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

Review 9.  Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.

Authors:  Hongyi Li; Yang Yang; Weiqi Hong; Mengyuan Huang; Min Wu; Xia Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-01-03

10.  Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.

Authors:  Blythe D Sather; Guillermo S Romano Ibarra; Karen Sommer; Gabrielle Curinga; Malika Hale; Iram F Khan; Swati Singh; Yumei Song; Kamila Gwiazda; Jaya Sahni; Jordan Jarjour; Alexander Astrakhan; Thor A Wagner; Andrew M Scharenberg; David J Rawlings
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.